---
schema_version: "secwatch.filing_event.v1"
accession: "0001665988-25-000016"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:35:36.479222+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q2 organic revenue up 6.2%; EPS $0.11 vs loss; reaffirms FY2025 guidance

## Summary
- Revenue $147.7M (-2.4% reported); organic revenue +6.2%, driven by double-digit growth in Surgical Solutions and Restorative Therapies.
- Diluted EPS $0.11 vs loss of $0.40; non-GAAP EPS $0.21, up 31% YoY on lower interest and equity compensation.
- Adjusted EBITDA $33.8M vs $34.5M; cash from operations $25.9M, up 71%.
- Reaffirmed FY2025 guidance: revenue $560-570M, Adjusted EBITDA $112-116M, non-GAAP EPS $0.64-0.68.
- Received FDA 510(k) clearance for TalisMann and StimTrial PNS systems in July 2025, addressing chronic nerve pain.

## SEC filing metadata
- accession: 0001665988-25-000016
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000166598825000016/0001665988-25-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000166598825000016/bvs-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001665988-25-000016
- JSON: https://secwatch.observer/filing/0001665988-25-000016.json
- Plain text: https://secwatch.observer/filing/0001665988-25-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.